StockNews.AI
EHC
StockNews.AI
27 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Encompass Health Corporation - EHC

1. Pomerantz LLP is investigating potential securities fraud at Encompass Health. 2. NY Times reports Encompass hospitals rank below average in safety measures. 3. 34 Encompass facilities have high rates of preventable readmissions. 4. Allegations include alarming mistakes leading to patient fatalities. 5. Encompass's stock dropped 10.35% after the article's publication.

4m saved
Insight
Article

FAQ

Why Bearish?

The article highlights serious safety and fraud allegations, causing stock decline. Similar situations in the past led to sustained stock drops for companies facing legal issues.

How important is it?

The allegations hold significant implications for Encompass's reputation, operations, and stock price, particularly amid investor concerns.

Why Short Term?

The immediate fallout from the news will provoke investor fear and potential class action, affecting short-term valuation. Historical examples show volatility after fraud allegations often lasts months.

Related Companies

HCAUHSKND
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Encompass Health Corporation (“Encompass” or the “Company”) (NYSE: EHC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Encompass and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On July 15, 2025, citing federal data and inspection reports, The New York Times published an article alleging that for-profit hospitals run by Encompass perform below average on key safety measures.  The article reported that “Encompass owns many of the rehabs with worse rates of potentially preventable, unplanned readmissions to general hospitals” including 34 facilities which “Medicare rated as having statistically significantly worse rates of potentially preventable readmissions.”  The article further described a number of “alarming mistakes” leading to fatalities of patients in the care of Encompass-owned facilities.  Following publication of the article, Encompass’s stock price fell $12.39 per share, or 10.35%, to close at $107.28 per share on July 15, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News